首页> 外文期刊>Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology >Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use.
【24h】

Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use.

机译:具有高风险心脏栓塞来源和先前使用华法林亚治疗的缺血性卒中患者在溶栓治疗后的安全性和结局。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Hemorrhage is a major complication of thrombolytic treatment. Concerns have been raised about the risk of hemorrhage in patients having received warfarin. Therefore, different indications for thrombolytic treatment are in use for stroke patients on warfarin. However, it remains uncertain whether the prior warfarin use actually increases their risk of bleeding in patients treated with thrombolysis. METHODS: This study included 179 consecutive patients who had high-risk cardioembolic sources and received thrombolytic treatment. Patients were treated with intravenous thrombolytic agents, or underwent intraarterial thrombolysis if their international normalized ratio (INR) was
机译:背景:出血是溶栓治疗的主要并发症。对于接受华法令的患者,出血的风险已引起关注。因此,使用华法令的卒中患者使用了不同的溶栓治疗适应症。然而,尚不确定先前使用华法林是否确实增加了溶栓治疗患者的出血风险。方法:这项研究包括179例具有高风险心脏栓塞来源并接受溶栓治疗的患者。患者接受静脉溶栓剂治疗,或者如果国际标准化比率(INR)为

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号